Journal: BMC Public Health
Article Title: Controversial Ebola vaccine trials in Ghana: a thematic analysis of critiques and rebuttals in digital news
doi: 10.1186/s12889-017-4618-8
Figure Lengend Snippet: Daily count of individual themes, shaded by number of articles per day mentioning a given theme. Themes were conceived as “statements about the trials,” and divided into two categories: critiques of the trials ( red ) and rebuttals on behalf of the trials ( green ). a Themes discussed in section " ": Descriptions of the trials as “secret” or “clandestine” were most prevalent in the first half of the controversy, but following Parliamentary discussions, this theme was superseded by the more restrained judgements that the trials had provided “insufficient information” to politicians and had failed to “sensitise” the general public. Trial representatives began responding in mid-June that information had been provided and public sensitisation would be done. b Themes discussed in section " ": Early concerns about the trials’ safety included two related but distinct fears – first, that trial participants might contract Ebola from the vaccine, and second, that because Ghana had no Ebola cases, the researchers must have intended to introduce Ebola into the population for the purpose of testing the vaccines. Rebuttals included repeated explanations of why the trial vaccines could not infect participants, as well as several assurances that Ebola was not being introduced to the country, however most rebuttals focused more on the idea that the trials were “following all protocols” and safe in a general sense. c Themes discussed in section " ": Incentives – 200 Ghanaian Cedis (GH₵) and a mobile phone – were a target for extensive criticism, both from those who felt these were valuable enough to be coercive, and also from those who perceived the trials to be very risky and consequently viewed the incentives as insultingly small. Rebuttals included the clarification that phones were intended to facilitate communication between researchers and participants, and the money was to compensate participants for their time. d Uncategorised themes
Article Snippet: Within its broader communication and community engagement mandate, EBODAC addressed the risk of misinformation and controversies undermining the trial of a prime-boost Ebola vaccine regimen, developed by Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).
Techniques: Introduce, Vaccines, Clarification Assay